{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:34Z","timestamp":1793744194106,"version":"4.6.1"},"reference-count":44,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2016,10,13]]},"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular carcinoma (HCC). Furthermore, we extended this exemplar to other models of virus-associated cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and results<\/jats:title>\n                  <jats:p>Clinical grade oncolytic orthoreovirus (Reo) elicited innate immune activation within primary human liver tissue in the absence of cytotoxicity and independently of viral genome replication. As well as achieving therapy in preclinical models of HCC through the activation of innate degranulating immune cells, Reo-induced cytokine responses efficiently suppressed HCV replication both in vitro and in vivo. Furthermore, Reo-induced innate responses were also effective against models of HBV-associated HCC, as well as an alternative endogenous model of Epstein\u2013Barr virus-associated lymphoma. Interestingly, Reo appeared superior to the majority of OVs in its ability to elicit innate inflammatory responses from primary liver tissue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We propose that Reo and other select proinflammatory OV may be used in the treatment of multiple cancers associated with oncogenic virus infections, simultaneously reducing both virus-associated oncogenic drive and tumour burden. In the case of HCV-associated HCC (HCV-HCC), Reo should be considered as an alternative agent to supplement and support current HCV-HCC therapies, particularly in those countries where access to new HCV antiviral treatments may be limited.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2016-312009","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T08:29:53Z","timestamp":1479284993000},"page":"562-573","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":64,"title":["Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer"],"prefix":"10.1136","volume":"67","author":[{"given":"Adel","family":"Samson","sequence":"first","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Bentham","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Scott","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Nuovo","sequence":"additional","affiliation":[{"name":"The Ohio State University, Comprehensive Cancer Centre, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Bloy","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Appleton","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Adair","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Dave","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Peckham-Cooper","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Toogood","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Nagamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases 1-23-1 Toyama, Tokyo, Japan"},{"name":"Oncolytics Biotech, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Vile","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"},{"name":"Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Molecular Medicine, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Errington-Mais","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Melcher","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5243","authenticated-orcid":false,"given":"Stephen","family":"Griffin","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James\u2019 University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"2025090722365406000_67.3.562.1","unstructured":"Boyle P , Levin B . World cancer report 2008. Lyon: International Agency for Research on Cancer, 2008."},{"key":"2025090722365406000_67.3.562.2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000000917","article-title":"Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center","volume":"260","author":"Franssen","year":"2014","journal-title":"Ann Surg"},{"key":"2025090722365406000_67.3.562.3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/SLA.0000000000000821","article-title":"A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients","volume":"261","author":"Utsunomiya","year":"2015","journal-title":"Ann Surg"},{"key":"2025090722365406000_67.3.562.4","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci Rep"},{"key":"2025090722365406000_67.3.562.5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/003335490612100611","article-title":"Self-reported hepatitis C virus antibody status and risk behavior in young injectors","volume":"121","author":"Hagan","year":"2016","journal-title":"Public Health Rep"},{"key":"2025090722365406000_67.3.562.6","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.051870"},{"key":"2025090722365406000_67.3.562.7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.578"},{"key":"2025090722365406000_67.3.562.8","doi-asserted-by":"publisher","DOI":"10.1002\/path.2592"},{"key":"2025090722365406000_67.3.562.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.004"},{"key":"2025090722365406000_67.3.562.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"2025090722365406000_67.3.562.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"2025090722365406000_67.3.562.12","unstructured":"NICE. Sorafenib for the treatment of advanced hepatocellular carcinoma | Guidance and guidelines | NICE. Published Online First: 2010. http:\/\/www.nice.org.uk\/guidance\/TA189 (accessed 6 Jul 2014)."},{"key":"2025090722365406000_67.3.562.13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/liv.12112","article-title":"Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma","volume":"33","author":"Lao","year":"2013","journal-title":"Liver Int"},{"key":"2025090722365406000_67.3.562.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.07.031"},{"key":"2025090722365406000_67.3.562.15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.65"},{"key":"2025090722365406000_67.3.562.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"issue":"7","key":"2025090722365406000_67.3.562.17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.000098","article-title":"Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma","volume":"96","author":"Jebar","year":"2015","journal-title":"J Gen Virol"},{"key":"2025090722365406000_67.3.562.18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"2025090722365406000_67.3.562.19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003578"},{"key":"2025090722365406000_67.3.562.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0334"},{"key":"2025090722365406000_67.3.562.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901074"},{"key":"2025090722365406000_67.3.562.22","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.60"},{"key":"2025090722365406000_67.3.562.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0503"},{"key":"2025090722365406000_67.3.562.24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1348-0421.1988.tb01476.x","article-title":"Suppression of HBsAg production in PLC\/PRF\/5 human hepatoma cell line by interferons","volume":"32","author":"Yamashita","year":"1988","journal-title":"Microbiol Immunol"},{"key":"2025090722365406000_67.3.562.25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072195"},{"key":"2025090722365406000_67.3.562.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25804"},{"key":"2025090722365406000_67.3.562.27","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.225"},{"key":"2025090722365406000_67.3.562.28","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.118"},{"key":"2025090722365406000_67.3.562.29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01080-07"},{"key":"2025090722365406000_67.3.562.30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/670437"},{"key":"2025090722365406000_67.3.562.31","doi-asserted-by":"publisher","DOI":"10.1038\/nature10168"},{"key":"2025090722365406000_67.3.562.32","doi-asserted-by":"publisher","DOI":"10.1038\/90968"},{"key":"2025090722365406000_67.3.562.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"2025090722365406000_67.3.562.34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75938"},{"key":"2025090722365406000_67.3.562.35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"2025090722365406000_67.3.562.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"2025090722365406000_67.3.562.37","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.055921-0"},{"key":"2025090722365406000_67.3.562.38","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.143"},{"key":"2025090722365406000_67.3.562.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803771"},{"key":"2025090722365406000_67.3.562.40","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.95"},{"key":"2025090722365406000_67.3.562.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-192443"},{"key":"2025090722365406000_67.3.562.42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210900200"},{"key":"2025090722365406000_67.3.562.43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302609"},{"key":"2025090722365406000_67.3.562.44","doi-asserted-by":"publisher","DOI":"10.1007\/BF00300234"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2016-312009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:37:15Z","timestamp":1757309835000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2016-312009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,8]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/gutjnl-2016-312009"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2016-312009","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}